IVVD Stock Overview
Invivyd, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States.
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 6/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Invivyd, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$4.44 |
52 Week High | US$5.20 |
52 Week Low | US$0.98 |
Beta | 0.61 |
1 Month Change | 3.74% |
3 Month Change | 12.69% |
1 Year Change | 274.68% |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -78.74% |
Recent News & Updates
Recent updates
We're Keeping An Eye On Invivyd's (NASDAQ:IVVD) Cash Burn Rate
Oct 24We're Keeping An Eye On Invivyd's (NASDAQ:IVVD) Cash Burn Rate
Jul 04Will Invivyd (NASDAQ:IVVD) Spend Its Cash Wisely?
Mar 19Is Invivyd (NASDAQ:IVVD) In A Good Position To Deliver On Growth Plans?
Nov 19Invivyd appoints interim CFO, makes headcount changes
Oct 13Adagio Therapeutics changes name to Invivyd, generates COVID-19 antibodies
Sep 12Adagio Therapeutics GAAP EPS of -$0.47
Aug 15We're Keeping An Eye On Adagio Therapeutics' (NASDAQ:ADGI) Cash Burn Rate
Jul 30Adagio names David Hering as permanent CEO and Director
Jul 05Adagio's Round Trip
Mar 02We're Interested To See How Adagio Therapeutics (NASDAQ:ADGI) Uses Its Cash Hoard To Grow
Feb 19Adagio: A COVID-19 Play With Big Potential On Possible Treatment And Prevention
Feb 16Adagio Therapeutics: The Market Is Too Crowded For Its Lead Drug Candidate
Nov 29Shareholder Returns
IVVD | US Biotechs | US Market | |
---|---|---|---|
7D | 43.7% | 0.9% | 0.4% |
1Y | 274.7% | 10.3% | 28.8% |
Return vs Industry: IVVD exceeded the US Biotechs industry which returned 9.6% over the past year.
Return vs Market: IVVD exceeded the US Market which returned 29.5% over the past year.
Price Volatility
IVVD volatility | |
---|---|
IVVD Average Weekly Movement | 17.7% |
Biotechs Industry Average Movement | 11.6% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.9% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: IVVD's share price has been volatile over the past 3 months.
Volatility Over Time: IVVD's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2020 | 85 | David Hering | https://invivyd.com |
Invivyd, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company’s lead product candidate is adintrevimab, a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease, as well as developing monoclonal antibody candidates, including VYD222 and VYD224, which provides neutralizing protection against SARS-CoV-2. It also has discovery stage candidates for the prevention of seasonal influenza.
Invivyd, Inc. Fundamentals Summary
IVVD fundamental statistics | |
---|---|
Market cap | US$475.39m |
Earnings (TTM) | -US$198.64m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.7x
P/E RatioIs IVVD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
IVVD income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$198.64m |
Earnings | -US$198.64m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -1.67 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0% |
How did IVVD perform over the long term?
See historical performance and comparison